drugset / Trial / NCT06610682
A Trial to Evaluate CSF ctDNA and Safety of Plixorafenib Alone or With Retifanlimab in Patients With BRAF-altered Glioma
Phase 0
Recruiting
24 enrolled
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Fore Biotherapeutics · collabIncyte Corporation · collabIvy Brain Tumor Foundation · collab
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The investigators will evaluate the sensitivity of ctDNA from plasma and CSF at baseline (defined as C1D1) and over time in response to treatment with plixorafenib alone or in combination with retifanlimab in patients with BRAF-V600E mutant glioma refractory to prior therapies.
Timeline
- Start
- 2025-04-07
- Primary completion
- 2027-06-30
- Completion
- 2028-06-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Plixorafenib | Small molecule | 900 mg | Oral |
| Subject | Retifanlimab | Monoclonal antibody | — | Intravenous |
Indications
No indication recorded.